Nixar (Bilastine)

Bilastine, the active ingredient in Nixar, is a second‑generation H1 antihistamine presented as an ocular formulation for eye use. It is employed to relieve the symptoms of allergic conjunctivitis in patients of all ages.\n\nGNH India supplies Nixar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bilastine acts on histamine‑mediated ocular allergy pathways to alleviate eye symptoms.\n\nAllergic conjunctivitis: reduces itching, redness and swelling of the conjunctiva.\nSeasonal allergic conjunctivitis: provides relief during pollen seasons.\nPerennial allergic conjunctivitis: controls symptoms caused by year‑round allergens.

Bilastine is generally well tolerated, but ocular administration can be associated with adverse reactions.\n\nCommon Side Effects:\n- Transient eye burning or stinging sensation.\n- Mild headache.\n- Temporary blurred vision.\n- Dry eye sensation.\n- Mild taste disturbance after drainage through the nasolacrimal duct.\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (anaphylaxis) with swelling of the face or throat.\n- Significant increase in intra‑ocular pressure.\n- Persistent eye pain or severe redness.\n- Vision loss or sudden visual disturbances.\n- Ocular edema or swelling of the eyelids.

Before using Nixar, consider the following safety measures.\n\nHypersensitivity: avoid if the patient has known allergy to bilastine or any excipients.\nHepatic impairment: use with caution in patients with severe liver dysfunction.\nConcurrent ocular drugs: do not combine with other antihistamine eye drops without medical advice.\nInfection monitoring: watch for signs of secondary eye infection during treatment.\nPregnancy and lactation: evaluate risk‑benefit ratio before prescribing.\nStore at room temperature: keep in the original container, protect from light and moisture.

Bilastine may interact with other agents that affect histamine pathways or drug metabolism.\n\nMajor Interactions (Avoid):\n- Potent CYP3A4 inhibitors (e.g., ketoconazole) may increase systemic exposure.\n- Concurrent use of systemic H1 antihistamines can lead to additive effects.\n\nModerate Interactions (Monitor Closely):\n- Alcohol may enhance mild sedation or dizziness.\n- Other ocular decongestants may increase irritation.\n- Systemic antihistamines may increase overall antihistaminic burden.